Atara Biotherapeutics, Inc.
ATRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -80.4% | -82.1% | 199.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96.7% | 96.8% | 79.2% | 79.3% |
| EBITDA | -$0 | $0 | $0 | -$0 |
| % Margin | -96.4% | 20.5% | 41.6% | -32.3% |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | -124.6% | 13.6% | 38.7% | -38.8% |
| EPS Diluted | -0.32 | 0.19 | 3.5 | -1.19 |
| % Growth | -268.4% | -94.6% | 394.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |